Phase I and II Agents in Cancer Therapy: Two Cisplatin Analogues and High‐Dose Cisplatin in Hypertonic Saline or With Thiosulfate Protection

Cisplatin is a chemotherapeutic coordination complex that has been evaluated extensively. It is particularly active against testicular cancer, but carcinomas of the ovary, bladder, cervix, and head and neck are also responsive. To increase efficacy and decrease toxicity, a number of platinum analogues have been developed and tested. One of these, carboplatin, is of particular interest. In clinical trials, it has demonstrated antitumor activity comparable to that of cisplatin, without evidence of significant renal toxicity or neurotoxicity. A second interesting platinum analogue is iproplatin. Preliminary phase I studies suggest reduced adverse renal and neurologic effects similar to those seen with carboplatin, with efficacy comparable to cisplatin. Attempts to overcome the dose‐limiting toxicity of cisplatin by administering high‐dose cisplatin (40 mg/m2/d for five days) in hypertonic saline or with thiosulfate protection are also reviewed. These techniques have eliminated nephrotoxicity as the dose‐limiting toxicity of cisplatin. However, nonrenal toxicity, especially neurotoxicity, remains substantial. The extent to which high‐dose cisplatin‐based chemotherapy should be used in routine clinical practice has not been determined.

[1]  J. Cowens,et al.  Studies on the pharmacokinetics and metabolism of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) in the dog. , 1982, Cancer treatment reports.

[2]  J. Mcvie,et al.  Phase I study and pharmacokinetics of intraperitoneal carboplatin. , 1985, Cancer treatment reviews.

[3]  R. Schilsky,et al.  Toxic effects of cis-dichlorodiammineplatinum(II) in man. , 1979, Cancer treatment reports.

[4]  R. Wheeler,et al.  Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat. , 1983, Cancer research.

[5]  Maccomb Ws.  Treatment of head and neck cancer. , 1960 .

[6]  S. Howell,et al.  High-dose cisplatin with sodium thiosulfate protection. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Pinedo,et al.  Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. , 1985, Cancer research.

[8]  Y. Ostchega,et al.  High-dose cisplatin in hypertonic saline. , 1984, Annals of internal medicine.

[9]  A. Howell,et al.  Activity of JM9 in advanced ovarian cancer: a phase I-II trial. , 1985, Cancer treatment reports.

[10]  L. Einhorn,et al.  The role of cis-platinum in solid-tumor therapy. , 1979, The New England journal of medicine.

[11]  E. Alba,et al.  Carboplatin, an active drug in advanced head and neck cancer. , 1986, Cancer treatment reports.

[12]  E. Wiltshaw,et al.  USE OF HIGH DOSE CIS‐DICHLORODIAMMINE PLATINUM (II) (NSC—119875) † FOLLOWING FAILURE ON PREVIOUS CHEMOTHERAPY FOR ADVANCED CARCINOMA OF THE OVARY , 1981, British journal of obstetrics and gynaecology.

[13]  D. Barnes,et al.  A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells. , 1985, Cancer research.

[14]  R. Ozols,et al.  A Phase I and Pharmacokinetic Study of Diamminecyclobutanedicarboxylatoplatinum (NSC 241240) , 1983 .

[15]  J. Venditti,et al.  Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. , 1984, Advances in pharmacology and chemotherapy.

[16]  R. Olshen,et al.  Intraperitoneal cisplatin with systemic thiosulfate protection. , 1982, Annals of internal medicine.

[17]  J. Yarnold,et al.  Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. , 1985, Cancer treatment reports.

[18]  Z. Siddik,et al.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. , 1984, Cancer research.

[19]  P. Loehrer,et al.  Drugs five years later. Cisplatin. , 1984, Annals of internal medicine.

[20]  P. Wiernik,et al.  Peripheral neuropathy after cis-platinum (II) (DDP) therapy. , 1980, Archives of physical medicine and rehabilitation.

[21]  B. Rosenberg.  Anticancer activity of cis-dichlorodiammineplatinum(II) and some relevant chemistry. , 1979, Cancer treatment reports.

[22]  J. Allen,et al.  Phase I study of carboplatin (CBDCA) in children with cancer. , 1986, Cancer treatment reports.

[23]  W. Rose,et al.  ANTITUMOR ACTIVITY OF PLATINUM ANALOGS , 1980 .

[24]  I. Smith,et al.  Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer. , 1985, Cancer treatment reviews.

[25]  C. Cohen,et al.  High-dose platinum for the treatment of refractory ovarian cancer. , 1981, Gynecologic oncology.

[26]  I. Smith,et al.  JM8 Development and Clinical Projects , 1984 .

[27]  M. Wolpert-DeFilippes.  ANTITUMOR ACTIVITY OF CISPLATIN ANALOGS , 1980 .

[28]  M. Egorin,et al.  Phase I clinical and pharmacologic trial of carboplatin daily for 5 days. , 1984, Cancer treatment reports.

[29]  A. Horwich,et al.  cis-Diammine-1, 1-cyclobutane dicarboxylate platinum II (carboplatin) in the treatment of testicular germ-cell tumours: a preliminary report. , 1985, Cancer treatment reviews.

[30]  Z. Siddik,et al.  Biliary Excretion, Renal Handling and Red Cell Uptake of Cisplatin and CBDCA in Animals , 1984 .

[31]  L. V. van Putten,et al.  Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives. , 1984, European journal of cancer & clinical oncology.

[32]  E. Gehan,et al.  Dose‐response and dose‐survival advantage for high versus low‐dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study , 1984, Cancer.

[33]  M. Egorin,et al.  Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. , 1984, Cancer research.

[34]  S. Crooke,et al.  Effects of second-generation platinum analogs on isolated PM-2 DNA and their cytotoxicity in vitro and in vivo. , 1980, Cancer research.

[35]  S. Howell,et al.  Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia. , 1980, Cancer treatment reports.

[36]  W. Rose,et al.  Antitumor activity and toxicity of cisplatin analogs. , 1982, Cancer treatment reports.

[37]  P. Wiernik,et al.  Ophthalmologic toxicity after cis-dichlorodiammineplatinum(II) therapy. , 1978, Cancer treatment reports.

[38]  E. Eisenhauer,et al.  Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study. , 1986, Cancer treatment reports.

[39]  N. Bachur,et al.  Cis‐dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms , 1980, Cancer.

[40]  W. Rose,et al.  Experimental Antitumor Activity of Platinum Coordination Complexes , 1984 .

[41]  K. Harrap,et al.  ANTITUMOR, TOXIC AND BIOCHEMICAL PROPERTIES OF CISPLATIN AND EIGHT OTHER PLATINUM COMPLEXES , 1980 .

[42]  E. Wiltshaw,et al.  Ovarian trials at the Royal Marsden. , 1985, Cancer treatment reviews.

[43]  N. Bachur,et al.  High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. , 1981, Cancer treatment reports.

[44]  C. Litterst.  Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration. , 1981, Toxicology and applied pharmacology.

[45]  P. Hydes.  Synthesis and Testing of Platinum Analogues — An Overview , 1984 .

[46]  D. Trump,et al.  Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms. , 1985, Cancer treatment reports.